Organovo Holdings Company Leadership
| ONVO Stock | USD 1.12 0.03 2.61% |
Organovo Holdings employs about 18 people. The company is managed by 21 executives with a total tenure of roughly 146 years, averaging almost 6.0 years of service per executive, having 0.86 employees per reported executive. Analysis of Organovo Holdings' management performance can provide insight into the firm performance.
| Taylor Crouch CEO President CEO |
| Keith Murphy Chairman Chairman, CEO and President Member of Audit Committee and Member of Science and Technology Committee |
Organovo |
Organovo Holdings Management Team Effectiveness
The company has return on total asset (ROA) of (0.7277) % which means that it has lost $0.7277 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3407) %, meaning that it created substantial loss on money invested by shareholders. Organovo Holdings' management efficiency ratios could be used to measure how well Organovo Holdings manages its routine affairs as well as how well it operates its assets and liabilities.Organovo Holdings Workforce Comparison
Organovo Holdings is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 7,103. Organovo Holdings adds roughly 18.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Organovo Holdings Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organovo Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organovo Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Organovo Holdings insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gobel David over three weeks ago Disposition of tradable shares by Gobel David of Organovo Holdings subject to Rule 16b-3 | ||
Keith Murphy over three months ago Acquisition by Keith Murphy of 19607 shares of Organovo Holdings subject to Rule 16b-3 | ||
Sharon Presnell over six months ago Payment of 9420 shares by Sharon Presnell of Organovo Holdings subject to Rule 16b-3 |
Organovo Holdings Notable Stakeholders
An Organovo Holdings stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Organovo Holdings often face trade-offs trying to please all of them. Organovo Holdings' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Organovo Holdings' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Taylor Crouch | President CEO | Profile | |
| Keith Murphy | Chairman, CEO and President Member of Audit Committee and Member of Science and Technology Committee | Profile | |
| Barry Michaels | CFO | Profile | |
| Sharon Presnell | CTO and Executive VP of RandD | Profile | |
| Michael Renard | Executive VP of Commercial Operations | Profile | |
| David Shapiro | Director | Profile | |
| Kirk Malloy | Independent Director | Profile | |
| Richard Maroun | Director | Profile | |
| Carolyn Beaver | Director | Profile | |
| Tamar Howson | Independent Director | Profile | |
| Robert Baltera | Independent Director | Profile | |
| Richard Heyman | Director | Profile | |
| James Glover | Independent Director | Profile | |
| Steve Kunszabo | VP, Investor Relations & Corporate Communications | Profile | |
| Eric David | Chief Strategy Officer | Profile | |
| Jeffrey Miner | Chief Officer | Profile | |
| Jennifer Bush | Compliance Officer, General Counsel, Corporate Secretary | Profile | |
| Paul Gallant | General Manager | Profile | |
| Vaidehi Joshi | Director Director | Profile | |
| MS JD | Gen Sec | Profile | |
| Curtis Tyree | Senior Development | Profile |
About Organovo Holdings Management Performance
The success or failure of an entity such as Organovo Holdings often depends on how effective the management is. Organovo Holdings management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Organovo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Organovo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. The company was incorporated in 2007 and is headquartered in Solana Beach, California. Organovo Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
The data published in Organovo Holdings' official financial statements usually reflect Organovo Holdings' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Organovo Holdings. For example, before you start analyzing numbers published by Organovo accountants, it's critical to develop an understanding of what Organovo Holdings' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Organovo Holdings' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Organovo Holdings' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Organovo Holdings' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Organovo Holdings. Please utilize our Beneish M Score to check the likelihood of Organovo Holdings' management manipulating its earnings.
Organovo Holdings Workforce Analysis
Traditionally, organizations such as Organovo Holdings use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Organovo Holdings within its industry.Organovo Holdings Manpower Efficiency
Return on Organovo Holdings Manpower
| Revenue Per Employee | 20.6K | |
| Revenue Per Executive | 17.6K | |
| Net Loss Per Employee | 958.8K | |
| Net Loss Per Executive | 821.9K | |
| Working Capital Per Employee | 743.2K | |
| Working Capital Per Executive | 637K |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organovo Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Organovo Stock, please use our How to Invest in Organovo Holdings guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Organovo Stock analysis
When running Organovo Holdings' price analysis, check to measure Organovo Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Organovo Holdings is operating at the current time. Most of Organovo Holdings' value examination focuses on studying past and present price action to predict the probability of Organovo Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Organovo Holdings' price. Additionally, you may evaluate how the addition of Organovo Holdings to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Organovo Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organovo Holdings. If investors know Organovo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organovo Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Organovo Holdings is measured differently than its book value, which is the value of Organovo that is recorded on the company's balance sheet. Investors also form their own opinion of Organovo Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organovo Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organovo Holdings' market value can be influenced by many factors that don't directly affect Organovo Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organovo Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organovo Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organovo Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.